Compare ResMed Inc. (RMD) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? ResMed Inc. trades at $225.83 (market cap $32.61B), while Direxion Daily FTSE China Bull 3x Shares trades at $28.98. The key difference: ResMed Inc. pays a 1.17% dividend while Direxion Daily FTSE China Bull 3x Shares pays none, and ResMed Inc. is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| RMD | YINN | |
|---|---|---|
Market Cap | $32.61B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $293.73 | $56.62 |
52-Week Low | $182.82 | $21.45 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.
The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.
YINN, a leveraged ETF tracking the FTSE China Bull 3x strategy, trades at $28.93, down 10.43% in 24 hours amid broad bearish technical signals. The fund lacks traditional financial ratios due to its structure, with a dividend of $0.21 scheduled for June 2026. Recent news highlights China's economic stimulus and AI investments, but geopolitical tensions and regulatory risks persist.
Outlook remains cautious due to leverage amplifying volatility; opportunities exist if Chinese equities rebound, but risks include US-China friction and economic slowdowns. Investors should weigh the ETF's high-risk profile against potential gains from China's tech growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
